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ABSTRACT
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Treatment.
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ADVISOR: Brian Cohen
The shared circuitries of depression and the stress response, regulated by the
Hypothalamic-Pituitary-Adrenal (HPA) axis, implies that major depression may reflect
dysregulations of the HPA axis. Previous studies find that that melancholic depression is
accompanied by hyperactive HPA activity, anxiety, insomnia etc. Adversely, patients with
atypical depression present CRH deficiency accompanied by lethargy and fatigue. According to
the corticosteroid receptor hypothesis, HPA axis dysregulation that causes these variable
phenotypic depressive moods may be attributed to defective GR expression or
function. Multiple GR polymorphisms that could impact its expression or function have been
identified. Due to limitations, it was not feasible to study a depressed patient population at this
time. Fortunately, the strong correlation between depression and obesity both being induced
HPA dysregulation means that a similar study can be done by examining metabolic disorders.

A diagnosis of Metabolic Syndrome (MS) requires patients to present three or more of
the following symptoms: elevated fasting blood glucose levels, elevated serum triglyceride
levels, low serum HDL levels, elevated blood pressure, and truncal obesity. This pathology
overlaps with Cushing’s Syndrome (CS) except a diagnosis of CS requires hypercortisolemia.This
similarity has led our lab and others to hypothesize that MS may be a Cushingoid-like state

caused by hypersensitivity of the glucocorticoid receptor (GR), a nuclear hormone receptor that
is activated upon the binding of cortisol. Using an allele specific polymerase chain reaction
(PCR) protocol, previous research in our lab found significant correlations between the BclI and
N363S polymorphisms of the GR and altered patient metabolic profiles in a population of
patients seeking bariatric surgery. This suggests that each contributes to obesity related
diseases. Recent work in our lab has expanded our study to include the cortisol resistance
polymorphism TthIII1 (rs10052957) to test the hypothesis that there would be a decreased
prevalence of this polymorphism in our subject population. The TthIII1 allele is present at a
lower frequency in our research population compared to reported frequencies, consistent with
our hypothesis.

In addition to investigating the glucocorticoid receptor, we have also developed an allele
specific PCR assay for previously identified single nucleotide polymorphisms (rs12086634 and
rs846910) in the cortisol reductase enzyme known as 11beta-hydroxysteroid dehydrogenase
(11b-HSD) type 1. The 11B-HSD1 enzyme converts inactive cortisone to cortisol, working
primarily in adipose tissue. The polymorphisms listed above are associated with overactivity of
the enzyme and may cause the Cushingoid-state observed in MS patients. In our patient
population, the frequency of heterozygosity for the rs12086634 SNP was nearly 50% higher
than the reported frequency in the general population, suggesting that this polymorphism may
contribute to increased obesity and the MS metabolic profile, by increasing the localized
cortisol in adipose tissue. Greater understanding of the interplay between these SNPs can help

physicians and patients make more informed decisions about treatment options for obesity and
metabolic syndrome.

Introduction
Cortisol: an overview
Cortisol is a glucocorticoid, steroid hormone that has a variety of physiological and
psychological effects throughout the body. Therefore, it is no surprise that cortisol and similar
synthetic analogs are commonly used to treat numerous diseases, ranging from dermatological
rashes to hematological malignancies0. With its viable receptors expressed in nearly all
mammalian cells, cortisol influences many different functions1. The hormone contributes to the
regulation and function of metabolic, cardiovascular, immune, and physiological and
psychological stress responses-- all of which are prone to agitation and essential to restore
following the stimulus of an acute stressor1,2.
Of its many target tissues, let’s first investigate cortisol’s role with respect to peripheral
tissues. Cortisol helps maintain energy homeostasis by regulating metabolism in times of both
health and disease. In the presence of a physiological stressor (famine, strenuous exercise etc.),
cortisol acts on the liver to increase gluconeogenesis and glycogenolysis, thereby restoring
glucose levels through the synthesis of smaller derivatives or the breakdown of glycogen0.
Cortisol impacts the catabolism of both lipids and proteins. By increasing insulin resistance, the
synthesis of very low-density lipoproteins, free fatty acid production, and the circulating levels
of very low-density lipoprotein and low-density lipoprotein, triglyceride and cholesterol levels
are increased0. Insulin resistance coupled with increased glucose levels induces greater insulin
levels, leading to greater fat storage. Cortisol influences the distribution and accumulation of
these increased fat levels in the abdominal region, often leading to obesity related diseases
when cortisol levels are high3,4.

Glucocorticoids are released from the adrenal gland in response to a stressor activating
the regulatory hypothalamic-pituitary-adrenal (HPA) axis. The role of the HPA axis is to maintain
normal glucocorticoid secretion. This neuroendocrine system is regulated by stress responses,
glucocorticoid signaling/feedback loops, and circadian rhythms2,5. In response to a perceived
stressor, afferent neurons send a stimulus to the paraventricular nucleus of hypothalamic
neurons, inducing the release of the hypothalamic hormones: corticotropin-releasing hormone
(CRH), vasopressin, and oxytocin2,6. These hormones control the release of ACTH from
corticotroph cells in the anterior pituitary6. Although vasopressin and oxytocin don’t induce
large secretions of ACTH independently, when in combination, the hypothalamic hormones
elicit more ACTH than CRH could on its
own2. ACTH then binds to receptors
on the adrenal cortex, where it
induces the synthesis and secretion of
glucocorticoids from the zona
fasciculata6.

Glucocorticoids are involved in
classic, multi-variable endocrine
13 .

Figure
The Hypothalamic-Pituitary-Adrenal (HPA) axis. The
numerous positive and negative feedback loops within this
neuroendocrine system are mapped out in a simplified manner. This
represents how stress initiates the pathway resulting in the production
of cortisol and other glucocorticoids.

feedback loops (Figure 1), which allow
for increased regulation of HPA stress

response and circulating glucocorticoid levels. CRH and ACTH stimulate an increase in
glucocorticoid levels, while glucocorticoids negatively feedback on the hypothalamus and

anterior pituitary to reduce the synthesis and secretion of CRH, vasopressin, and ACTH
respectively6. Interestingly, glucocorticoids have no feedback inhibition on oxytocin2. The
circadian rhythm is determined by the activity of the hypothalamic suprachiasmatic
nucleus2,5. Glucocorticoid secretions begin to spike just before waking, due to the presence of
CRH and an increase in the adrenal response to ACTH2. This phenomena, known as the cortisol
awakening response, leads to peak cortisol levels within a half hour of waking5. Cortisol levels
then decrease relatively steadily in a diurnal rhythm, hitting a trough in the late evening2,5.
90-95% of secreted glucocorticoids are bound to corticosteroid-binding globulin (CBG), a
carrier protein, increasing its solubility in water, allowing glucocorticoids to travel effectively
through the circulatory system1. When cortisol arrives at a target tissue, disassociation with the
CBG occurs, leaving behind a biologically available, lipid soluble steroid that can cross the cell’s
bilayer, bind to its receptor, enter the nucleus, and bind to its specific DNA region. Cortisol
binds to both the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR), though
its affinity for the MR is ten times stronger than its affinity for the GR7. The GR and MR share
many similarities both in structure and in expression, explaining why cortisol acts as a ligand for
both receptors8. Structurally, their DNA binding domains are 94% homologous9. While the MR
is expressed in peripheral tissues, it is highly expressed throughout the limbic regions of the
brain, specifically in the hippocampus, amygdala and prefrontal cortex2,7. The GR is expressed
more ubiquitously throughout the limbic system, especially in the hippocampus, the prefrontal
cortex, the paraventricular nucleus of the hypothalamus, the dentate gyrus, and the amygdala7.
GRs are also present in corticotrophs and other peripheral tissues7.

Considering that cortisol has a higher affinity for the MR, when at low levels, cortisol
binds to MRs. Therefore, MRs are responsible both for feedback inhibition of the HPA axis at
resting cortisol levels, and for starting the stress response2,8. As cortisol levels rise above the
resting rate, GR binding becomes more common8. The GR terminates the stress response and
promotes memory storage to better prepare the body to respond to that same stimulus in the
future8. At these higher cortisol levels, though the MR is involved, it is the GR that is the
primary contributor to HPA axis feedback inhibition8. In a study from 2011 investigating the
relationship between glucocorticoids and the immune system, Zen et al., found that both the
MR and the GR shared related immunosuppressive functions9. Though sample size was cited as
a primary limitation in a similar study performed by Cheng et al., (2016) they found that during
low dose cortisol treatments, the blocking effects on cortisol-mediated inflammation regulation
were similar regardless of whether monocytes’ GRs or MRs were inhibited8.

The Glucocorticoid Receptor
The cortisol-MR interaction establishes an individual's basal response and control of the
HPA axis. In addition, glucocorticoids have a lessened effect through the MR because MRs, in
most tissues excluding the brain, are shielded by 11ß-Hydroxysteroid dehydrogenase II (11ßHSDII), which converts the active cortisol into its inactive metabolite, cortisone0. Therefore,
researchers are mostly interested in investigating how GRs, which play a larger role in the stress
response, impact HPA axis regulation0-4.
The GR is a nuclear
receptor encoded by NR3C10.
Located on chromosome 5, it

has

nine exons, and follows a
normal nuclear receptor
composition: there is an Nterminus transactivation
domain, a C-terminus ligand
binding domain, with a DNA

Figure 20. Glucocorticoid Receptor Isoforms, formed by multiple
promotor sequences in the 9 exons, alternative splicing, different
translational start signals, and post translational modifications.

binding domain in between7.
The 9 exons create the opportunity for multiple splice variants which, combined with
alternative translation, result in functional diversity within the GR7. GRalpha is the biologically
active isoform7. GRß, (a result of the splice variant lacking helix 12) cannot bind glucocorticoids,
but can still regulate other genes7. GRgamma is still biologically active, but has significantly less
transcriptional activity compared to GRalpha7.

The GC-GR complex modulates target gene transcription through both genomic and
non-genomic pathways7. After ligand binding, the GR-GC complex traffics towards the nucleus
and mediates transcription in one of many different ways. It can promote GR-GR dimerization
on the glucocorticoid response element leading to chromatin remodeling, which induces
transactivation7. If the glucocorticoid binds to a negative GC response element (located in the
promoter of a target gene), gene transcription will be inhibited. Glucocorticoids’ nongenomic
actions include influencing T-cell receptor signaling, increasing cellular energy metabolism,
modulating apoptosis, and changing behavior7.

HPA Axis dysregulation and its implications on cortisol, stress and depression
As mentioned previously, the numerous variables and regulatory combinations in the
HPA axis and its control system increase its ability to maintain equilibrium when activated, as
there are multiple checkpoints where homeostasis can be restored. However, this also means
that there are more places for things to go awry. Aberrant HPA activity, or HPA dysregulation in
general, is linked with various psychiatric disorders as well as obesity8. HPA axis dysregulation
is measured through a Dexamethasone suppression test (DST) or a Dexamethasone-CRH
combined test (DEX/CRHT). In a DST, up to 2 mg of dexamethasone (an exogenous
glucocorticoid) is administered to measure the adrenal negative feedback on the pituitary7. This
provides information on an individual’s baseline feedback levels0,2. DEX/CRHT is a refined DST
that is a bit more accurate. In this test, 1.5 mg of dexamethasone is administered at around
11:00 PM, when an individual's natural cortisol levels should be low7. At around 3:00 PM the

following day, 100 µg of CRH is administered7. Meanwhile, cortisol and ACTH levels are
collected every 15 minutes from 2:00 to 6:00 PM7,8. This test provides information on how
effective the positive and negative feedback loops of and individuals HPA axis are, and is the
most sensitive measure of HPA overactivity associated with depression2.
The association between HPA axis dysregulation and depression, especially unipolar and
bipolar depressive disorder, has been established for decades7. Spijker et al., (2009) found that
80 percent of patients with a major depressive episode were non-suppressors in response to
the DEX/CRHT, further highlighting the linkage between HPA axis dysregulation and
depression7. This dysregulation, leading to Major Depression Disorder (MDD) and Bipolar
Depression (BD) is connected to anatomical and neuroendocrine alterations in brain function-including changes in catecholamines and serotonergic neurotransmission7. Specifically,
glucocorticoids were found to intensify the extent that dopamine affects the brain's reward
system7. Patients with depression were also found to have anatomical changes and altered
metabolic activity in their prefrontal cortex, amygdala, and hippocampus7. Patients with
depression have hypometabolism in frontal regions, and hypermetabolism in the right
hippocampus. Interestingly, the metabolic levels normalize with antidepressant treatment.
Stress, which activates the HPA axis, can be defined as an actual (physical) or perceived
(psychological) threat to the well being of an organism2. A stressed stimulus can be acute (brief)

or chronic (long term). Physical and
mental health is dependent on the
HPA’s ability to regulate stress. HPA
axis dysregulations are associated
with different neuropsychiatric
diseases. HPA overactivity is
associated with typical or melancholic
depression, panic disorder, OCD and
schizophrenia0,1,2,8. These are often
Figure 323. The Neuropathology of stress. Comparing the interactions
between the prefrontal cortex, the stress response, and the immune
system normally (left) vs. during chronic stress (right). Note the HPA
axis dysfunction on the left.

characterized by elevated 24-hour
free cortisol, and enlarged adrenal

glands6. Low HPA axis activity is characteristic of atypical depression8.
Chronic stress induces GR dysfunction or resistance (Figure 3), which often leads to the
synthesis and secretion of more cortisol in an effort to overcome the receptor resistance7.
However, the HPA response has been shown to be habituated or sensitized, after repeated
exposure to a stressful stimulus11. The scientific community believes that the observed interindividual variability of HPA axis response to repeated stimuli may be caused by GR
variants11. Depression, therefore, may be a result of defective GR expression or function in the
brain and corticotroph, based on different GR variants or isoforms in the tissue of interest2. This
idea lead to the formation of the Corticosteroid receptor hypothesis, which explains how
depression and the subsequent treatment impact HPA activity12. This can be broken down into
two parts. The first part identifies the connection between depression and defective GR

expression or function, which results in a loss of inhibitory feedback, represented by
dexamethasone resistance, causing basal HPA activity to rise. This, in turn, results in the
increased production of ACTH-releasing factors leading to an increased ACTH response to
DEX/CRHT13. Additionally, post mortem evidence of individuals diagnosed with MDD suggests
they have fewer cerebral GRs and MRs. The second part identifies that proper treatment can
overcome receptor deficits2.
Due to the fact that the GR isoforms all originate from the same gene, NR3C1, GR
function is greatly impacted by mutations in that gene. Numerous single-nucleotide
polymorphisms (SNPs) of the NR3C1 gene have been identified, and are associated with
neuropsychiatric diseases as well as altered lipid and carbohydrate profiles14. While many
studies have examined the phenotypic SNPs with respect to the corticosteroid receptor
hypothesis, they all contain discrepancies due to differences in drug effects and treatment
times, indirect autoregulatory effects from differences in glucocorticoid secretion,
heterogeneity of study populations, and the fact that subtypes of depression have varying types
of HPA dysfunction15.
The
BclI SNP
is caused
by a
C→G
415.

Figure
Location of Single Nucleotide Polymorphisms (SNPs) of the NR3C1. While there are
other identified SNPs of the Glucocorticoid Receptor, TthIII1, ER22/23EK, N363S, BclI, and GR-9ß
are the best studied.

nucleotide change in intron 2, 646 nucleotides downstream of the respective intron
junction0. BclI polymorphisms are associated with glucocorticoid hypersensitivity0. Studies have
found that unfavorable metabolic characteristics including insulin resistance, diminished
salivary cortisol responses, and increased abdominal visceral fat, body mass index (BMI), waist
to hip ratio (WHR), and leptin and cortisol responses to a standardized lunch are all associated
with the G-allele carriers11. Three different studies looked at the prevalence of homozygous
mutant BclI carriers in a depressed group compared to a control group7. All three studies found
that depressed group had roughly 15.5% homozygous mutant, while the control group had
9.9% express the mutant phenotype homozygously7. These studies established a relationship
between the SNP, MDD, and obesity.
N363S is another GR hypersensitivity polymorphism that is the result of an asparagine to
serine (N→S) amino acid change in codon 363 of exon 2, which is the result of an AAT→ AGT
nucleotide change7. A meta-analysis combining 12 studies and containing 5,909 individuals
aged 25 or older, found that N363S carriers had increased BMI (+0.51 kg/m^2) compared to
non-carriers0. In addition to increased BMI, the SNP is associated with higher WHR, increased
cortisol suppression, and increased salivary cortisol in response to an acute psychosocial
stressor11. Additional GR hypersensitivity SNPs of interest are RS7701443 and RS296315624.

The ER22/23EK SNP is a linked GAG.AGG→GAA.AAG nucleotide change in codons 22 and
23 of the transactivation domain7. The first nucleotide change is silent, as both forms code for
glutamic acid (E)16. However, the second nucleotide change switches the amino acid from
arginine (R) to lysine (K)16. This variant is associated with GC resistance, as carriers have a

decreased response to DST7,11,15,16. They also had lower fasting insulin levels, and lower lipid
profiles than noncarriers16. The polymorphism is associated with recurrent depression and
improved responses to antidepressant medication7. Multiple studies comparing GR SNP
haplotype frequencies in depressed versus normal populations found that the unipolar MDD
group carrier frequency was 8-11% compared to a healthy control group where only 4% carried
the polymorphism7.
Another GR resistance polymorphism is TthIII1, which is an SNP caused by a C→T change
6,305 base pairs upstream of the first initiation codon0. Initial findings suggested that TthIII1
carriers had higher basal cortisol levels, due to altered promoter activity, however this is still
inconclusive, as other research suggests that TthIII1 only has effects when expressed in
combination with other SNPs including ER22/23EK or BclI0.
Glucocorticoids have numerous, differential effects based on an individual's
glucocorticoid sensitivity. This sensitivity, and glucocorticoids subsequent action on target
tissues, is, in part, determined by genetics and the functional NR3C1 polymorphisms listed
above. In addition, steroid access to MRs and the enzyme 11ß-HSD also play critical roles in
regulating glucocorticoid concentrations.

The 11ß-HSD I and II isoforms regulate how much active metabolite is available to bind
to receptor24. Through

peripheral

conversion, 11ß-HSDII

converts

the active metabolite,

cortisol,

into the inactive
metabolite, cortisone, and
adipose tissue19. This

Figure 5. The Redox reaction conducted by the 11ß-HSD
isoforms, in order to peripherally convert cortisone into
cortisol, and vice-versa

stores it in
creates a

reservoir of potential cortisol stored away in fat. The type I isoform works to access this stored
cortisone by converting it into cortisol25,26. 11ß-HSD is localized in adipose, liver, and lung
tissue2. 11ß-HSDII often guards MRs, converting cortisol into its inactive metabolite before it
can act on the receptor2. This is why GR polymorphisms are more strongly associated with HPA
dysregulation, even though glucocorticoids have greater affinity for MRs than GRs. Therefore,
SNPs leading to 11ß-HSD I overactivity are also of special interest as they are pertinent to HPA
axis regulation, and can cause dysregulations that promote neuropsychological disease,
metabolic syndrome, and related comorbidities25,26. Two Identified SNPs that induce 11ß-HSD I
overactivity are RS12086634 and RS84691025,26.
The big picture is that the GR plays a vital role in mammalian function. The GR and its
associated polymorphisms impact HPA axis control and cortisol levels. A study by Tronche et al.,
(1998) found that GR knockout mice were unviable, dying within minutes after birth due to
collapsed lungs as a result of uncontrolled inflammation3.

Neuropsychiatric treatments and their effects on HPA regulation

Numerous antidepressants currently on the market have been associated with
decreasing the pituitary-adrenal hyperactivity common in typical depression. These include
tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), Bupropion,
Mirtazapine (alpha2-adrenergic antagonist), and electroconvulsive shock therapy2. Longitudinal
studies where the aforementioned treatments were provided individually or in combination
showed increased ACTH response to the CRH/DST as well as the normalization of HPA hormone
secretion to circadian patterns and a reduction in adrenal gland volume if enlarged2. However,
these findings are not universal across other similar studies.
From these treatments, it is understood that good treatment can overcome receptor
deficits, by increasing/improving either the function or expression of the receptors, however
we do not yet understand how antidepressants mechanistically normalize HPA
activity2. However, it has recently been found that antidepressants affect GR expression
differently in different parts of the brain10. Atypical depression, for example, could be
successfully treated with either glucocorticoid interference or glucocorticoid
supplementation. Glucocorticoid interference would be necessary if the GR is overactive or
over-stimulated by high levels of glucocorticoids. Glucocorticoid supplementation would be
necessary if the receptor is hyposensitive to cortisol or if cortisol levels are just too
low. Therefore, in order to properly treat an individual, we need to know their cortisol levels in
combination with their GR and 11ß-HSD haplotype, meaning the SNPs they carry.
Understanding and accounting for patient heterogeneity within the context of HPA regulation is
the largest obstacle to overcome in order to successfully treat depression.
HPA Axis Overactivity and Obesity

Factors in major depression are directly linked to metabolic dysfunction, and even
promote susceptibility to heart disease27. Since cortisol is essential to lipid and carbohydrate
homeostasis, HPA overactivity often induces metabolic dysfunctions leading to, for example,
Cushing’s syndrome (CS), which is characterized by hypercortisolemia18,27. For this reason, CS is
associated with MDD, anxiety disorder, other psychological diseases, and even reduced
hippocampal volume7. Classically, CS patients present obesity related symptoms including
dyslipidemia, hypertension, glucose intolerance, and increased visceral adiposity1,18,19.

Figure 727. Factors in major depression that promotes metabolic dysregulation and related comorbidities.

The World Health Organization reports that worldwide obesity has more than doubled
since 198020. With the increased rates in obesity comes a rise in obesity related symptoms
including insulin resistance, high triglycerides, high blood pressure, low HDL-cholesterol and
central adiposity19. Having three out of the five stated symptoms is sufficient in order to
diagnose Metabolic Syndrome (MS)19. Patients with CS and MS share all of the same
symptoms, except while CS is characterized by hypercortisolemia, MS is associated with normal

or even low cortisol levels. The lack in a mechanistic understanding of MS has lead to the
following hypothesis: MS may be a cushingoid-like state with normal cortisol levels,
accompanied by GR hypersensitivity and/or overactive 11ß-HSD I.
The increased rate of obesity is linked with the popularization of bariatric surgery-- a
method to treat morbid obesity. Currently there are three main forms of bariatric surgery: the
Roux-en-Y gastric bypass, the sleeve gastrectomy and the lap-band. Studies show that bariatric
surgery can greatly alter metabolic pathways, inducing HPA axis dysregulation, which affects
weight loss and leads to comorbidities including hypertension, hyperlipidemia, and depression,
through mechanisms explained previously22. Therefore, the post-bariatric population works as
an experimental group representative of MS.
The purpose of this study is to first determine the prevalence of GR hypersensitivity
SNPs (BclI, N363S, RS7701443, RS2963156), GR resistance SNPs (TthIII1, ER22/23EK), and 11ßHSD SNPs (RS12086634, RS846910), in an obese, post-bariatric population compared to a
control or random population composed of college students. In addition, we want to see how
the presence of individual SNPs and haplotypes correlate with metabolic parameters, including
BMI, blood glucose, serum triglycerides, HDL and LDL cholesterol, and systolic and diastolic
blood pressure in the bariatric patient population. We also hope to determine whether there is
a correlation between the presence of certain SNPs or haplotypes and the success of specific
bariatric surgeries. We hope that these findings can aid both healthcare providers and
potential bariatric patients when determining how to best treat or manage their weight.

Methods

Figure 8. Summary of Research Approach

DNA Collection – Ellis Bariatric Center
DNA was collected from bariatric patients at Ellis Bariatric Center in Schenectady, NY.
Ellis Hospital’s Institutional Review Board approved the study prior to collection beginning
(Appendix A). Prior to saliva collection, all potential participants were instructed on the
purpose of the study and provided with the option to sign an informed consent form (Appendix
B). If consent was granted, the participant would pour ~10 mLs of a 0.1% saline solution in their
mouth, swish it around for 20-30 seconds, and spit it out into a collection cup. The wash
product was transferred into a 15 mL centrifuge tube and labeled with the participant’s medical
record number (MRN).

DNA Isolation – Ellis Bariatric Patients
Chelex 100 beads by Bio-Rad© protocol was used to isolate the DNA (Appendix C).

Isolated DNA collection—Union College
Union College’s Human Subjects Review Committee approved this study prior to DNA
collection (Appendix D). The Union students who participated in this study had previously
collected and isolated their DNA using the same methods as described above. After instructing
them on the purpose of the study, Union students were given an instruction sheet with a
random sample number and a few questions (Appendix D), and an informed consent form
(Appendix B). If they consented, they filled out the questions and transferred the contents of
their remaining isolated DNA into a 1.5 mL centrifuge tube, which they then labeled with the
random number on their instruction sheet.

Data Collection – Ellis Bariatric Center
The relevant surgery and metabolic parameters of participating patients was collected by
searching the individuals MRN in Ellis Bariatric Center’s electronic medical records (EMR). Type
of surgery, surgery date, pre-surgery weight (PSW), PSW date, original weight, height, starting
BMI, lowest weight (LW), LW date, lowest BMI, current weight (CW), CW date, current BMI,
fasting blood glucose, serum triglycerides, Serum LDL, Serum HDL, systolic blood pressure and
diastolic blood pressure was collected. Using that information, ideal body weight, excess body
weight (EBW), weight lost, and %EBW lost, was calculated.

Allele-specific PCR

By entering the known DNA sequences of desired SNP’s into Web Based Allele Specific Primer
(WASP), wild-type (WT) and mutant (MT) primers were designed to bind specifically to a target
polymorphism. Based on annealing temperatures, a desired primer set, consisting of common
primer that ran in opposition to both the WT and MT primer, was selected (See Appendix E for
various WASP results and selected primer information).

PCR tubes had a total volume of 50 µL, which was broken down into the component reagents
according to Table 1 below.
Table 1. Reagent Quantities per PCR Tube
Reagent

Quantity

1) Common Primer

1 µL

2) WT or MT Primer

1 µL

3) DNA Template

8 µL

4) dNTPs

0.5 µL

5) Taq polymerase

0.5 µL

6) Buffer

5 µL

7) DI Water

34 µL

Table 2. Tested Oligonucleotides
Primer
Common

Wild Type

Mutant

BclI

BClI.down.new

BClI.up.WT.new

BClI.up.MUT.new

N363S

N363.2/4F

N363S.down.WT.new

N363S.down.MUT.new

RS120

rs12086634.com.f

rs12086634.wt.r

rs12086634.mut.r

RS84

rs846910.com.r

RS846910.wt.f

RS846910.mut.f

RS770

rs7701443.gr.com.r

rs7701443.gr.wt.f

rs7701443.gr.mut.f

RS296

rs2963156.gr.com.r

rs2963156.gr.wt.f

rs2963156.gr.mut.f

TthIII1

rs10052957.TthIII1.com.f

rs10052957.TthIII1.wt.r

rs10052957.TthIII1.mut.r

ER/EK

rs6190.EREK.com.f

rs6190.EREK.wt.r

rs6190.EREK.mut.r

Gel Electrophoresis
Gel electrophoresis was used to analyze primer-binding efficiency, in order to first optimize the
primer sets, and then subsequently genotype patients. The PCR reactions were processed
through a 3% gel at 100 V, which ran for roughly 30 minutes. The gel was stained with ethidium
bromide so bands could be detected under the UV light from G:BOX SYNGENE (Appendix G).

Results
PCR optimization

Using the annealing temperature calculated by the selected WASP result as a starting point,
various PCR trials were run for each SNP until an Optimized annealing temperature was
identified. PCR reactions were run in a Bio Rad C1000 Thermal Cycler. As seen in Table 3 below,
six of the eight target SNPs were originally optimized.
Table 3. Optimized PCR Annealing Temperature for each SNP
Polymorphism
Annealing Temp (°C)
BcI1

52°

Unfortunately, due to reasons still not fully

N363

55°

understood, BclI, N363S, TthIII1, and RS12086634 were

RS12086634

52°

RS846910*

-

RS7701443

52°

RS2963156

55°

TthIII1

61°

ER/EK*

-

* Signifies failure to optimize

the only primers that continued to work throughout
the entire genotyping process.

Genotyping of Participants

Figure 9. An aggregation of the gel electrophoresis results for each of the four fully optimized SNPs.
This figure includes subjects 25, 26, 27,28, 29 & 31 from the Union College student population

Genotyping was determined based on the method described in the Gel Electrophoresis section.
Appendix G has additional agarose gel electrophoresis results. Figure 9 demonstrates what the
genotyping looked like. A complete account of individual genotype and relevant clinical
information is in appendix H.

Prevalence of the SNPs
Based on the genotyping results, the total genotypic and allelic frequencies of both the random
and the bariatric populations could be compared for each optimized SNP.

Table 4. The genotypic and allelic break down for all successful Ellis patients and Union students

There was
no
significant
difference
between the random and bariatric population for the genotypic and allelic frequencies of
NR3C1 hypersensitivity SNPs (BclI and N363S). However, TthIII1, a GR resistance SNP, was
present at a much lower allelic frequency in the bariatric population compared to the random
population tested and the frequency listed in the literature. In addition, the RS12086634 SNP,
associated with overactive 11ß-HSD I enzyme activity, was present at a much higher frequency
in the bariatric population compared to the random population.

Discussion:
In this study, we hypothesized that metabolic syndrome may be a cushingoid-like state
with normal cortisol levels, accompanied by GR hypersensitivity and/or overactive 11ß-HSD I.
Based on our collected allelic frequencies, we found that the bariatric population not only had
increased peripheral conversion of cortisone into the active metabolite cortisol, but it also
lacked cortisol resistance polymorphisms. These allelic frequencies support our hypothesis that
cortisol signaling and regulation is a contributing factor to morbid obesity, and can potentially
bridge the mechanistic gap between Cushing’s Syndrome and Metabolic Syndrome.
There is plenty of statistical analysis that still needs to be done to the collected data,
which will aid in strengthening conclusions. First, haplotype analysis must be performed
extensively. As of now, all that is known is the overall allele frequencies of the four optimized
SNPs. Haplotype analysis is necessary in order to examine whether certain SNP combinations
have larger impacts on HPA axis dysregulation than they would independently. It will be helpful
to compare allelic frequencies with metabolic parameters and bariatric surgery success.
In addition, to adding haplotype analysis, we must broaden our approach by not just
examining more SNPs within the current areas of study (NR3C1 and 11ß-HSD I), but looking to
see how other receptors and genes and signaling factors play a role. The MR is very much
impacted by glucocorticoid signaling and plays a role in HPA axis regulation. Studies by Spijker
et al., (2009) suggest that there is a connected pathophysiology between the GR and the MR
involved in glucocorticoid signaling.

The MR becomes even more relevant when this research project begins genotyping
depressed individuals, for cerebral MRs are not guarded by 11ß-HSD II, and therefore play a
stronger role impacting neuropsychology compared to metabolism.
There are two other interesting areas to explore that could reveal relevant information
about HPA axis regulation. Considering that only the free, unbound glucocorticoids can have a
biological effect, levels of CBG, may influence cortisol bioavailability1. Severe CBG mutations
have been associated with both chronic fatigue syndrome (CFS) and increased fat
distribution28,29. There was also a correlation with hypocortisolism, a classic culprit for CFS29.
The second new area to introduce, which would improve this study, is to look more in
depth at glucocorticoid receptor signaling. Clearly, a variety of factors including glucocorticoid
concentrations, local glucocorticoid availability, HPA regulation, genetics/relevant
polymorphisms, and NR3C1 receptor affinity all affect glucocorticoid sensitivity. Another
interesting factor are disruptions in glucocorticoid signaling. Major depression is often
characterized by HPA axis overactivity and high levels of cytokines17. In fact, inflammation is a
key feature in some depression and obesity cases. A study with 35 healthy men and women
identified a shared pathophysiology of immune dysregulation in both depression and
obesity8. How is this possible if cortisol, in addition to cortisol’s many effects mentioned
earlier, is also acts as a strong anti-inflammatory? It has to due with the way cytokine signals
access the brain and interact with pathophysiologic pathways (i.e. disrupt GR activity) relevant
to mood regulation17.

Figure 617. Cytokine-Glucocorticoid Receptor signaling pathways interactions These simplified signal transduction
interactions demonstrates the complex inhibitory and induction relationships between cortisol, the GR and cytokines.

Cheng et al., (2013) discovered that inflammation regulated by GC-GR is the
pathophysiological link between depressive symptoms and obesity. They identified a peripheral
loop of bidirectional association within the GR signaling pathway when in the presence of
inflammation. The peripheral blood monocytes of stressed individuals’ contained lower levels
of glucocorticoid response element expression, but an increase in inflammatory transcription
factors8. Varying cytokines impacted the HPA axis, disrupting GR secretion, GR translation and
GR posttranslational modifications. Therefore, depression induces inflammation dysregulation
via GR insensitivity to glucocorticoids on immune cells, which results in an inflammation
dysregulation that in turn promotes further glucocorticoid insensitivity8.

Due to the feasibility of acquiring a metabolic syndrome patient population compared to
a depressed patient population, this study was first initiated on a bariatric population. Because
of the connectedness of depression, specifically MDD, with dyslipidemia, insulin resistance and
hypertension, we can extend this exact research method to depression. The Institutional
Review Board at Albany Medical College has approved that very project, which will hopefully
begin the summer of 2017.
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Appendix
A- Ellis IRB Form and approval

BELLIS HOSPITAL
CINSTITUTIONAL REVIEW BOARD
DAPPLICATION FOR RESEARCH PROJECT
EF- Project:
G- Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly
Obese Patients
HI- Name, Title and Position of Principal Investigator (s):
J- Anne Jones, RN
KL- Co-Investigators:
M-Brian D. Cohen, PhD, Senior Lecturer, Union College Dept. of
Biological Sciences
NO- Purpose of Project:
P- To characterize the presence of glucocorticoid receptor polymorphisms
associated with obesity in patients undergoing bariatric surgery
procedures.
QR- Describe Population for Study:
S- The population for the study will be patients who are preparing for or
have undergone bariatric surgery procedures for treatment of morbid
obesity.
TU- Has IND # been obtained, if applicable: ___
IND# _________
V- Has NDE # been obtained, if applicable:
NDE#_________
WXY- Probable Time Project May Take:
Z- Initial studies are projected for 5 months but may extend depending on
enrollment rate
AABB- Probable Starting Date :
CC- 1/5/14
DDEE- Potential Hazards and Precautions:
FF- There are no potential hazards or precautions for the subjects or the
investigators
GG-

HH- Potential Inconveniences or Discomforts to Subjects and Other
Pertinent Clinical Information:
II- Subjects will be asked to swish a sterile saline solution in their mouths
for 30 seconds which some subjects may find unpleasant.
JJKK- Estimated Number of Human Subjects Required:
LL- We are currently targeting 100 subjects as a starting group, although
we are hoping for a larger subject pool if possible
MMNN- Estimated Duration of Study:
OO- Initial study is projected for 5 months, although extension of the
study may be requested depending on the rate of enrollment of subjects.
PPQQ- Have You Discussed This Protocol With Other Practitioners
Affected?
RR- YES___
NO_X__
If Yes, with Whom?
SSTTUU- Approval Must be Obtained from the Director of Pharmacy for
Protocols
VV- Involving Investigational New Drugs Before IRB Review.
WWXX- Not Applicable
YYDirector of Pharmacy
ZZAAAApproval Must be Obtained from the Director of Materials
Management (Purchasing) for Protocols Involving Non-Approved
Devices or the Purchase of New Devices Before IRB Review.
BBBCCCNot Applicable
DDDDirector of
Materials Management
EEEFFF- Source of Funds:
GGGMaterials for isolating and analyzing patient DNA will be
provided from the Union College Student Research Grant Fund and the
Union College Faculty Research Fund
HHHIII- Facilities to be Utilized:
JJJ- DNA sample, demographic, and clinical information collection will be
done at the Ellis Bariatric Offices
KKKDNA analysis will be done at Union College in Dr. Cohen’s
research lab.

LLLMMMHave you or are you in the process of undertaking training
or certification in the area of Human Subject Research?
NNNYes _____
No__X___
OOOPPP- If Yes, Please provide a copy of the certification with this application.
QQQRRRSSS- Do you have any Relationship with the Study Sponsor, Manufacturer
of the Device or Medication in which you are investigating that should
be disclosed?
TTTYes _____
No___x__
UUUVVVIf Yes, please explain:
_______________________________________________
WWWXXXNote: Research that has been approved by the IRB may be
subject to further appropriate review by Hospital administration if Ellis
Hospital’s resources are to be utilized in this study.
YYYZZZSignature of Department Chair/Division
Chief:__________________________
AAAABBBBTen (10) copies of the Protocol
and/or Informed Consent need to be delivered (electronic copy
preferred) to the IRB Chair, Michael Pasquarella, A-Ground, Ellis
Hospital, at least One Week prior to the meeting.
CCCC-

1101 Nott Street

Schenectady, New York 12308

Phone: (518) 243-4011

www.ellismedicine.org

December 23, 2014
Anne Jones RN
Brian D Cohen PhD
Ellis Medicine Bariatric Care Center
2125 River Road Suite #302
Niskayuna, NY 12309

Re: Prevalence of Glucocorticoid Receptor Polymorphisms in Morbidly Obese Patients

Dear Ann and Dr. Cohen
Thank you for attending the December 18, 2014 meeting of the Institutional Review Board. Under
full board review the protocol, informed consent (with changes) and other materials presented for
the above mentioned study were approved. The study was approved for 2 years with an interim
report due at the June 2015 IRB meeting. As a reminder, no additional changes may be made to
this project without first submitting the changes to the IRB for review. Any inquiries or
unanticipated problems must also be promptly reported.
Thank you for your continued interest in medical research.
Sincerely,

Michael V. Pasquarella
Michael V. Pasquarella Pharm.D., R.Ph.
Chairperson
Institutional Review Board

cc: Pat Biggica

B- Ellis Participant Informed Consent

Informed Consent Form
The purpose of this research project is to look for a correlation between polymorphisms of
the glucocorticoid receptor (variations in the DNA sequence of the natural receptor for the
hormone cortisol) and clinical manifestations of obesity and related comorbidities such as
elevated blood sugar, blood pressure, increased waist/hip circumference ratio, and altered
serum lipid profiles.
Agreeing to participate in this study means that you will allow the testing of your DNA for
the purposes of identifying receptor variations and you are agreeing for relevant medical
data to be provided to the researchers to compare with the receptor variations. You will not
receive information about your individual results from this study. Your DNA will not be used
for any other purpose or analyzed in any other way. After 2 years, your DNA sample will be
destroyed.
Your decision about whether or not to participate will not affect your treatment by Ellis
Bariatric Medicine. You will not be compensated for your participation in the study.
If you decide to participate you will be asked to perform a mouthwash with sterile saline that
will allow us to recover cells from inside your cheek. Some people find the salty taste of the
saline wash a little unpleasant but should provide no significant discomfort or risk for you.
Identification of which genetic variant(s) of this gene you have will not affect your treatment
in any way. As information is gathered about the relationship between variations of the
cortisol receptor gene and obesity (and related diseases), it may eventually help identify
opportunities for complimentary therapies for obesity, but this is beyond the scope of the
present study. Currently we are strictly interested in determining if there is a connection
between this gene and obesity (and related diseases) and any discovery will not affect your
treatment plan.
Your DNA sample will be coded with your patient identification number instead of your
name before it is given to researchers at Union College for DNA analysis. The researchers
will also be given access anonymously to relevant medical information from your records
required to complete the study. Records given to Union College researchers will only have
your patient ID number and not your name. Relevant medical information will include but
not strictly be limited to:
1. Your weight before you began treatment
2. Your height
3. Your waist to hip ratio or waist circumference (where available) before you began
treatment
4. Fasting blood sugar
5. Serum triglycerides

6.
7.
8.
9.

Serum LDL and HDL
Blood pressure
Related medications that you are taking that might affect these measures
Treatments you receive at Ellis Bariatric such as medications and surgical procedures

Your DNA sample will be kept in the laboratory of Dr. Brian Cohen at Union College and will
only be accessible to him or to his student researchers working on this research project.
Similarly, relevant medical information made available to Dr. Cohen will only be available to
him or his student researchers and will not be accessible to anyone else at Union College.
Although we do not anticipate making any discoveries that would alter your care or cause
you to wish to drop out of the study, if any such discoveries are made the medical staff of
Ellis Bariatric will contact you and give you the option to withdraw from the study. Choosing
to withdraw from the study will in no way affect your care as a patient of Ellis Bariatric. We
anticipate that more than 100 patients will be a part of the study and the more patients that
are included, the more significant any findings will be.
If you have any questions, please ask Anne Jones, RN, CBN, at Ellis Bariatric or Dr. Brian
Cohen, Union College. Their contact information can be found below. You will be asked to
sign one copy of this informed consent form and will be given a copy to keep for your records.
The choice to be in this study and to stay in this study is strictly voluntary. Refusal to
participate will involve no penalty or loss of benefits which you are otherwise entitled. You
may discontinue your participation at any time with no penalty or loss of benefits which you
are otherwise entitled. If you wish to leave the study, please contact Ms. Anne Jones and
inform her that you wish to withdraw from the study. You will be asked to sign a written
form indicating your desire to withdraw. Ellis Bariatric will then inform Dr. Cohen of your ID
number and your DNA sample will be destroyed and your relevant medical information will
be removed from the data set.
Thank you for considering being a part of this research study. If you have any questions
before participating or at any time during the study, please do not hesitate to contact us.
Anne Jones, RN, CBN
Ellis Bariatric Medicine
jonesa@ellismedicine.org
518-831-7030
Michael Pasquarella, PharmD, RPh
Chair, Institutional Review Board
Ellis Hospital
pasquarellam@ellismedicine.org
518-243-1818

Brian D. Cohen, PhD
Union College
cohenb@union.edu
518-388-8018

1. I have been informed about the purpose of this genetic test and experimental research project.
2. I understand that I will not receive the results from the testing.
3. I have been informed as to who may have access to my biological sample, and that the laboratory
may retain any leftover sample until the end of the study, at which point it will be destroyed.
4. I have read the material provided and this consent form in full. My questions have been
answered to my satisfaction.
5. I consent to provide a sample for genetic testing and to have relevant medical data provided
anonymously to the researchers.
6. I understand that my participation is completely voluntary and I may withdraw at any time
without affecting my care as a patient of Ellis Bariatric.

______________________________________________________________________________
Signature
Date

C – DNA Extraction Protocol
Isolation of Crude Human Genomic DNA samples suitable for PCR
The source of DNA that you will use for PCR reactions next week will be your cheek cells, which will be obtained by a sterile
saline mouthwash. The cells are collected by centrifugation and resuspend in a solution containing the resin "Chelex", which binds
metal ions that would otherwise inhibit the PCR reaction. The cells are then lysed by boiling, and centrifuged to remove cell debris
and the Chelex resin. The result is a crude genomic DNA prep that is "good" enough for PCR!
You should have the following materials available before you start:
Materials:
Microfuge tubes and racks; micropipettors and tips
One 15 ml plastic “Blue-top” tube
One Non-sterile (but unused) plastic “Dixie” cup
One plastic transfer pipette
Labelled Waste container for “spit” waste
Microfuge tube containing 1.2 ml of 10% Chelex (labeled “Chelex")
Shared Materials:
Clinical Table-top Centrifuge for pelleting cells
Boiling water baths with “floatie” for boiling samples
Microfuge
1) Get a boiling water bath ready for use in step 8. Fill up an ice bucket halfway using crushed ice obtained from the Biology
“autoclave room” on the third floor.
2) Label a 15 ml tube (blue-top) with your initials on the top and the side of the tube, and pipette (or carefully pour) 10 ml of sterile
saline into the tube. Label a new microfuge tube with your initials, also on the top and side of the tube.
3) Pour all of the saline solution into your mouth (don't swallow it!), and vigorously swish for 15 seconds. Carefully expel the fluid
into a plastic Dixie cup, and then pour the liquid back into the 15 ml tube and reclose the cap.
4) Place your tube in a clinical centrifuge balanced against another tube opposite it in the rotor. Try and fill up the rotor if you can
with tubes from other members of the class. Centrifuge for 10 minutes at 1,000 X g for 10 minutes to pellet the cells.
5) After the spin is over, use a transfer pipette to pipette off as much of the supernatant as possible into the labeled waste
container (we'll autoclave this later). Pipette off the liquid so that the cells remain with only a minimal amount of liquid (approx 200
µL). You might have to briefly (1 min.) spin the tube again if the cells get dislodged from the side/bottom of the tube during this
process. Resuspend the cells in the minimal volume of remaining supernatant by vortexing, and then transfer the whole volume
using the same plastic transfer pipette to a new, labelled microfuge tube. Vortex this tube containing the cells for 5-10 seconds,
making sure that there are no clumps of cells remaining.
6) Resuspend the Chelex beads (in the microfuge tube labeled "10% Chelex") by vortexing for 10 seconds. Before the beads have

had a chance to settle, pipette 500 µL of Chelex solution into your microfuge tube containing the cells.
7) Resuspend the cells in the Chelex by vortexing for 10 seconds. Make sure that no cell clumps remain.
8) Incubate the microfuge tube containing the cells/Chelex mixture in the boiling water bath for 10 minutes, using a plastic "floatie".
Other peoples' tubes will also be boiled at the same time in the water bath, so make sure that your tube is labelled well!
9) Remove the floatie carefully from the boiling water bath, take your tube and incubate it on ice for two minutes. Spin the tube in
a microfuge (max. speed) for 1 minute to pellet the Chelex and cell debris to the bottom of the tube.
10) Using a 200 µL pipette, carefully transfer 200 µL of the supernatant (pipette from the top) to a new, labeled (with your initials)
microfuge tube. Avoid transferring any of the pelleted cells or the Chelex. Discard the tube containing the pellet. YOUR PREP IS
DONE AT THIS POINT! You should store your genomic DNA in the fridge in a labeled box or tube rack.

D- Human Subjects

UNION COLLEGE HUMAN SUBECTS REVIEW COMMITTEE
2016-2017 APPLICATION TO ENGAGE IN RESEARCH INVOLVING HUMAN SUBJECTS
For full instructions, please visit http://bit.ly/hsrc
Please type your responses in the fields provided. The grey fields will expand if more space is needed. When
completed, please print and deliver to Joshua Hart, Chair of the Human Subjects Review Committee, Bailey
Hall 302. Emailed, hand-printed, or unsigned applications will be returned unreviewed. Blue links can be
followed by holding the “control” key and clicking.
1a. Name of student researcher (if applicable) > Justin Salm
Box number > 1826
Email address > salmj@union.edu
Major > Biology
1b. Name of student researcher (if applicable) > Brianna Godlewski
Box number > 703
Email address > godlewsb@union.edu
Major > Biology
2. Name of faculty researcher or sponsor > Brian Cohen
Office location > Wold 220
Email address > cohenb@union.edu
Department > Biology
3. Title of project > Prevalence of Polymorphisms in the stress related genes in an Undergraduate Population
4. Is this research funded? > SRG funds requested for materials
If yes, by whom? >
5. Approximate number of participants: > 64
Approximate age range of participants: > 18-21
Other important characteristics of participants (e.g., prisoners, minors, participants in poor mental or
physical health, etc.) > None
6. Where will the data be collected? > Union College
7. If data will be collected at a location other than Union College’s campus, identify how you secured
permission from the appropriate individuals at the other location(s). Include this individual’s name and
contact information. > N/A
8. How will participants be sampled, recruited, or otherwise enlisted? > Participants will be BIO 225 Students

9. What rewards, payment, or other credit will be provided for participation, if any? > None
10. How will the anonymity of participants and/or the confidentiality of the data be ensured? > The DNA samples
will be given a random number and students will be asked to transfer the DNA into the new tube so that the tubes will not
have any other identifying marks. The number on the DNA sample will be correlated with the form containing information on
whether the student has previously been diagnosed with depression and the students height and weight. The form will have
no identifying information other than the matching number for the DNA sample. Once filled out, the student will fold the
form, tape it shut, and hand it to their lab professor. The lab professor will then give the completed forms and related saliva
samples to the researchers.

For the following items, indicate YES or NO. If the answer is YES, please explain.
11. Is it reasonably possible that any of the participants will be placed at risk with regard to physical
pain or discomfort, psychological stress or discomfort, or social injury (e.g., diminished reputation or
damaged social or personal relationships)? > No
12. Will information that might affect participants’ willingness to participate be withheld from them
prior to securing informed consent to take part in the research? > No
13. Will there be any coercion or penalties that might negate a participant’s freedom to refuse to
participate in the study or withdraw from participation? > No
14. Will any of the researchers who will be conducting the study be placed at risk with regard to
physical or psychological pain, discomfort, or harm? > No
15. Will any deception be involved? If so, explain the nature of the deception, the need for the
deception, and how risks from that deception will be mitigated. > No
16. Will topics or questions about depression or about thoughts of or attempts to engage in of selfinjury or suicide be included? > Yes. For part a of this project, the goal is to establish a correlation between
specific gene polymorphisms in an undergraduate student population and depression. For this research, it is
imperative to know whether the DNA sample belonged to an individual with depression. However, due to the
precautions explained in question 10 above, this information can only be related back to the DNA sample, not the
student.

For the following items, indicate YES or NO. If the answer is NO, please explain.
17. Will all promises and commitments made to the participants regarding their participation be duly
honored by the researcher? > Yes
18. Will it be made clear from the onset of the study that participants are free to withdraw from the
study at any time? > Yes

19. Immediately following their participation, will all participants be provided with a complete
explanation (debriefing) of the nature of the study so as to eliminate any possible misconceptions about
its purpose and to eliminate any stress or discomfort experienced by participants? > Yes
20. If payment is offered, immediately following their participation, will all participants be provided
with payment as promised (e.g., credit for course, gift certificate, etc) ? > Yes

21. The United States Government, via 45CFR46.116(d), states that informed consent must be obtained from
participants unless, among other criteria, it is not practicable to do so.
If you do plan to obtain informed consent, please indicate how, whether it be an informed-consent form,
a clickable button on a Website, or via other documentable means: > An informed-consent form
If you do not plan to obtain informed consent, please explain how your study meets each of the four
criteria for waiving this requirement as set forth by 45CFR46.116(d). > N/A

22 (OPTIONAL). In addition to the specific explanations that may have been provided with the responses to
items #11 through #21, you are welcome to provide any further comments that might help the Committee
determine whether the proposed research is likely to produce benefits so significant as to outweigh any
questionable or risk-producing research procedures. >

PLEASE ATTACH THE FOLLOWING APPENDICES.
APPENDIX W: Briefly explain the purpose of the research and provide a general description of the methods to
be employed (200 words should be sufficient).
The research attempts to examine the presence of specific polymorphisms located in the glucocorticoid receptor, the
mineralocorticoid receptor and the enzyme 11-ß HSD1 to establish a relationship between the relevant polymorphisms
and depression (part a) or obesity(part b). To do so, cells extracted from patients’ cheek cells can be tested for the
presence of the polymorphisms using a PCR method, and data can be collected on their height and weight to find the
patients’ BMIs. The student population represents a control group that could then be compared to a group of depressed
patients (part a) and morbidly obese bariatric patients (part b) to establish a difference in the prevalence of the
polymorphisms in the different populations. Because cheek cell samples are already being collected in BIO 225 as part of
an experiment, we would simply ask the students consent to use their DNA samples for our experiment as well as
provide whether they have previously been diagnosed with depression and their height and weight.

APPENDIX X: Provide a copy of the informed consent materials you plan to administer to participants (unless
you have made a case for not using one in #21. Whether you use the sample form found here or the OHRP
checklist found here, please ensure that your form contains all the elements called for by OHRP.

INFORMED CONSENT FORM

Our names are Brianna Godlewski and Justin Salm and we are students at Union College in Schenectady, NY. We are
inviting you to participate in a research study. Involvement in the study is voluntary, so you may choose to participate or
not. Participation in the study will not affect your grade in BIO225. Your instructor will not know if you have
participated or not. A description of the study is written below.
Our research is interested in determining if there is a relationship between variations in sequences of genes associated
with stress responses and the prevalence of obesity and depression. You will be asked to provide access to the DNA
sample that you generated for your BIO225 lab and ask you to answer a few questions including your height and weight
and if you have ever been diagnosed with depression. If you choose to participate in the study, we will ask you to put
your DNA from lab into a new tube labeled with an arbitrary number and also to fill out a separate form marked with the
same number. This will take approximately 5 minutes. There are no foreseeable risks to taking part in this study. If you
no longer wish to continue, you have the right to withdraw from the study, without penalty, at any time.
Your responses will be anonymous: the arbitrary number will not be connected to you in any way so we will not be
able to identify who filled out each form or whose DNA is being analyzed.
All DNA samples collected will be destroyed after analysis, no later than 7/1/17.
By signing below, you indicate that you understand the information above, and that you wish to participate in this research
study.

__________________________________
__________________
Participant Signature

________________________________
Printed Name

Date

APPENDIX Y: Provide a copy of all materials to be used in your study. If an interview procedure is to be
used, a detailed list of the types of questions that will be asked should be described. If participants will be
exposed to any stimuli, copies of those stimuli should be presented. In the case of oral presentations, a
transcript is sufficient. To be clear: anything a participant will read, see, be asked, or answer needs to be
included here.
Instructions:
1. If you choose to participate, please sign the informed consent form.
2. Regardless of your decision to participate, please fold over the informed consent form, tape it closed,
and return it to your instructor. This way neither your instructor nor your peers will be able to tell if you
have chosen to participate.
3. Please transfer your DNA to the new tube, regardless of whether or not you choose to participate in the
study.
4. If you choose to participate in the study, please complete the form below. If you choose not to
participate in the study, do not complete the form below.
5. Regardless of your decision to participate, please fold the form over, tape it closed and return this form
and your DNA to your instructor. This way neither your instructor nor your peers will be able to tell if
you have chosen to participate.
6. After class we will review the forms and keep only those samples where the form has been completed.

Sample Number:___________________________
Height (ft and in) _______________

Weight (lbs) _______________

Have you ever been diagnosed with depression? (Y/N) ________

APPENDIX Z: Provide a copy of the debriefing to be presented to participants, either in
text or orally. A debriefing statement is a statement presented to participants after their
participation. It should provide some information about the research study in which they
just participated. It need not provide detailed discussions to include literature reviews or
full hypotheses, but it should provide the participants with at least a basic understanding
of what the research is about. If it is not feasible to provide a debriefing, please explain
why.
Because we will not know which students have chosen to participate, we do not intend to
provide a debrief.
CERTIFICATION: I/we certify that:

The statements herein are factual to the best of my/our knowledge;
I/we have described our methods and materials accurately and completely;
I/we have not begun data collection in any way and will not do so until given HSRC approval;
If the proposal is approved, I/we will not make any modifications to the study until receiving additional HSR
approval;
I/we understand that the approval, if granted, expires one year from the initial approval date.
____________________________________
Student researcher (if applicable)
date
____________________________________
Student researcher (if applicable)
date

________________________________
Faculty researcher/advisor
date

E- WASP Results
i. N363S
AS Primer Picking Result for SNP2015-01-22
Input sequence 5':
ATTAAGGATAATGGAGATCTGGTTTTGTCAAGCCCCAGTAATGTAACACTGCCCCAA
GTGAAAACAGAAAAAGAAGATTTCATCGAACTCTGCACCCCTG
GGGTAATTAAGCAAGAGAAACTGGGCACAGTTTACTGTCAGGCAAGCTTTCCTGGA
GCAAATATAATTGGTAATAAAATGTCTGCCATTTCTGTTCATGG
TGTGAGTACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCCCTTT
CTCAACAGCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCA
ATTCCCGTTGGTTCCGAAA[A/G]TTGGAATAGGTGCCAAGGATCTGGAGATGACAAC
TTGACTTCTCTGGGGACTCTGAACTTCCCTGGTCGAACAGTT
TTTTCTAATGGCTATTCAAGCCCCAGCATGAGACCAGATGTAAGCTCTCCTCCATCC
AGCTCCTCAACAGCAACAACAGGACCACCTCCCAAACTCTGCC
TGGTGTGCTCTGATGAAGCTTCAGGATGTCATTATGGAGTCTTAACTTGTGGAAGCT
GTAAAGTTTTCTTCAAAAGAGCAGTGGAAGGACAGCACAATTA
CCTATGTGCTGGAAGGAATGATTGCATCATCGATAAAATTCGAAGAAAAAACTGCCC
AGCATGCCGCTATCGAAAATGTCTTCAGGCTGGAATGAACCTG
GAAGCTCGAAAAACAAAGAAAAAA
Sequence Size: 720
Primer Picking Parameters:
Primer Size
Opt: 20 Min: 18 Max: 36
GC%
Opt: 50.0 Min: 20.0 Max: 85.0
Tm
Opt: 55.0 Min: 40.0 Max: 65.0
Max Tm Diff:
100.0
Max Self Complementarity: 8.0
Max 3' Complementarity: 3.0
Max PolyX in Primer:
3
Number Primer Return: 5
Mismatch at the penultimate primer position: 'Yes'
In-silico PCR Filtering: 'No'
Mispriming Filtering: 'No'
Oligo 1 :
Any Self End
Wildtype Forward Primer 5':
ATTCCCGTTGGTTCCGAATA
Mutant Forward Primer 5':
ATTCCCGTTGGTTCCGAATG
Common Reverse Primer 5':
GCTTACATCTGGTCTCATGC
Product Size: 141

Pos.
301

Len.
20

Tm

61.41

GC% Self
45.00

5.00

2.00

301

20

64.11

50.00

5.00

2.00

441

20

55.83

50.00

4.00

2.00

-------------------------------------------------------------------------------------Oligo 2 :
End
Wildtype Forward Primer 5':
TTCCCGTTGGTTCCGAATA
Mutant Forward Primer 5':
TTCCCGTTGGTTCCGAATG
Common Reverse Primer 5':
TTACATCTGGTCTCATGCTG
Product Size: 138

Pos.
302

Len.

19

Tm

61.21

GC% Self Any Self
47.37

5.00

2.00

302

19

64.06

52.63

5.00

2.00

439

20

54.65

45.00

4.00

2.00

-------------------------------------------------------------------------------------Oligo 3 :
End
Wildtype Forward Primer 5':
TCCCGTTGGTTCCGAATA
Mutant Forward Primer 5':
TCCCGTTGGTTCCGAATG
Common Reverse Primer 5':
TTACATCTGGTCTCATGCTG
Product Size: 137

Pos.
303

Len.

18

303

59.85

18

439

Tm

50.00

62.86

20

GC% Self Any Self
5.00

55.56

54.65

2.00

5.00

45.00

2.00

4.00

2.00

-------------------------------------------------------------------------------------Oligo 4
: N363S.new
Any Self End
Wildtype Reverse Primer 5':
AGATCCTTGGCACCTATTCCATT
Mutant Reverse Primer 5':
AGATCCTTGGCACCTATTCCATC
Common Forward Primer 5':
ATACAGCATCCCTTTCTCAA
Product Size: 101

Pos.
342

23

342
242

Len.
62.17

23
20

Tm

43.48

62.67
54.87

GC% Self
4.00

47.83
40.00

1.00

4.00
3.00

0.00
1.00

-------------------------------------------------------------------------------------Oligo 5 :
End
Wildtype Reverse Primer 5':
GATCCTTGGCACCTATTCCATT
Mutant Reverse Primer 5':
GATCCTTGGCACCTATTCCATC
Common Forward Primer 5':
AATACAGCATCCCTTTCTCA
Product Size: 101

Pos.

Len.

341

22

341
241

22
20

Tm
61.38
61.89
54.87

GC% Self Any Self
45.46
50.00
40.00

4.00
4.00
3.00

1.00
0.00
1.00

ii. TthIII1
AS Primer Picking Result for rs10052957
Input sequence 5':
CTTACGGAATTTAATTGAAGAGATGAACTCCAGTGTGCCAGAAAGGACGTGAGATTTAGCATTATAATAATAACACAAT
TCTAACGAAAGTCAACATTTA
TTGCGCATCTGCTGTCTGACAGACACTATTGAAAGTGTTTTATGCACAGTATCCTAAGTCTTTAGGTATGGCATTTACT
AATCTGTAACCCTGGGAACTT
ATAATTACTACAAGAAATAGGATGAATCCCTATCTGAGTGGGAAGGTATTTGATTGTCTTAGAAGCAGAGGTGGAAATG
AAGGTGATGTATTCAGACTCA
[A/G]TCAAGGCAAGGACCTGATCTATCTTGTCATAGCTTTATGTCCCACTCCTGGAACACAGCCCACTACATAGCAGG
CACCCAACAAATACATTACAG
GGTTATAATAACATTGAGTCAACTAGTTAACTAGATGTAAAATCACTTTTACTGGGTTATTGTTGTGGCCAAATGGGTT
AATAAAAAGTGTACAGATAAC
CCTCAAGATCCTCATTTTTATTGTTTTGTGTTTAAACATCTGAGTGCTCCCCCCACTTTTTTTTAAAATAAACTAGATT
AGATTCTTGATTGTATGTTCT
TATAG
Sequence Size: 601
Primer Picking Parameters:
Primer Size
Opt: 20 Min: 18 Max: 36
GC%
Opt: 50.0 Min: 20.0 Max: 85.0
Tm
Opt: 55.0 Min: 40.0 Max: 65.0
Max Tm Diff:
2.0
Max Self Complementarity: 5.0
Max 3' Complementarity:
3.0
Max PolyX in Primer:
3
Number Primer Return:
5
Mismatch at the penultimate primer position: 'Yes'
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000
Mispriming Filtering: 'Yes' Form Human Library
Oligo 1
:
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
AGATAGATCAGGTCCTTGCCTTGTT
325
25
62.71
44.00
5.00
1.00
Mutant Reverse Primer 5':
AGATAGATCAGGTCCTTGCCTTGTC
325
25
63.21
48.00
5.00
1.00
Common Forward Primer 5':
TGAACTCCAGTGTGCCAGAAA
24
21
61.82
47.62
4.00
0.00
Product Size: 302
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 2
:
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
GATAGATCAGGTCCTTGCCTTGTT
1.00

Pos.

324

24

61.98

Len.

45.83

Tm

5.00

Mutant Reverse Primer 5':
GATAGATCAGGTCCTTGCCTTGTC
324
24
62.48
50.00
5.00
1.00
Common Forward Primer 5':
GATGAACTCCAGTGTGCCAGA
22
21
61.28
52.38
4.00
3.00
Product Size: 303
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 3
:
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
ATAGATCAGGTCCTTGCCTTGTT
323
23
60.37
43.48
5.00
1.00
Mutant Reverse Primer 5':
ATAGATCAGGTCCTTGCCTTGTC
323
23
60.85
47.83
5.00
1.00
Common Forward Primer 5':
ATGAACTCCAGTGTGCCAGA
23
20
59.26
50.00
4.00
3.00
Product Size: 301
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 4
:
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
TAGATCAGGTCCTTGCCTTGTT
322
22
60.13
45.46
5.00
1.00
Mutant Reverse Primer 5':
TAGATCAGGTCCTTGCCTTGTC
322
22
60.63
50.00
5.00
1.00
Common Forward Primer 5':
ATGAACTCCAGTGTGCCAGA
23
20
59.26
50.00
4.00
3.00
Product Size: 300
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 5
:
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
AGATCAGGTCCTTGCCTTGTT
1.00
Mutant Reverse Primer 5’:
AGATCAGGTCCTTGCCTTGTC
1.00
Common Forward Primer 5':
GAACTCCAGTGTGCCAGAAA
0.00
Product Size: 297

Pos.

321

321

25

21

60.13

21

20

60.64

58.85

Len.

47.62

52.38

50.00

Tm

5.00

5.00

4.00

In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------

iii. ER22/23EK
AS Primer Picking Result for rs6190
Input sequence 5':
GGATTGCATTGTACTTTTAAATGTGGCATGCTGAATGGGAGCAGGGGACATGGCTTTTTATTCTGGAAGATAGAAACTA
CTCTTCTGGTAACAAAGAATT
TGATTCGGAGTTAACTAAAAGGTTCATTTAACAAGCTGCCTCTTACTAATCGGATCAGGAAGATAATGTGACTTTAGAG
CTTATGATGTTTTCCCCCCGT
TTTTGTTTTTTGTTTTGTAGTTGATATTCACTGATGGACTCCAAAGAATCATTAACTCCTGGTAGAGAAGAAAACCCCA
GCAGTGTGCTTGCTCAGGAGA
[A/G]GGGAGATGTGATGGACTTCTATAAAACCCTAAGAGGAGGAGCTACTGTGAAGGTTTCTGCGTCTTCACCCTCAC
TGGCTGTCGCTTCTCAATCAG
ACTCCAAGCAGCGAAGACTTTTGGTTGATTTTCCAAAAGGCTCAGTAAGCAATGCGCAGCAGCCAGATCTGTCCAAAGC
AGTTTCACTCTCAATGGGACT
GTATATGGGAGAGACAGAAACAAAAGTGATGGGAAATGACCTGGGATTCCCACAGCAGGGCCAAATCAGCCTTTCCTCG
GGGGAAACAGACTTAAAGCTT
TTGGA
Sequence Size: 601
Primer Picking Parameters:
Primer Size
Opt: 20 Min: 18 Max: 36
GC%
Opt: 50.0 Min: 20.0 Max: 85.0
Tm
Opt: 55.0 Min: 40.0 Max: 65.0
Max Tm Diff:
2.0
Max Self Complementarity: 5.0
Max 3' Complementarity:
3.0
Max PolyX in Primer:
3
Number Primer Return:
5
Mismatch at the penultimate primer position: 'Yes'
In-silico PCR Filtering: 'Yes' with Max Product Size: 4000
Mispriming Filtering: 'Yes' Form Human Library
Oligo 1
:
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
TAGAAGTCCATCACATCTCCAT
322
22
56.18
40.91
4.00
2.00
Mutant Reverse Primer 5':
TAGAAGTCCATCACATCTCCAC
322
22
56.70
45.46
4.00
0.00
Common Forward Primer 5':
AGGTTCATTTAACAAGCTGC
120
20
54.71
40.00
5.00
3.00
Product Size: 203
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 2
:
GC%
Self Any
Self End
Wildtype Reverse Primer 5':

Pos.

Len.

Tm

AGAAGTCCATCACATCTCCAT
321
21
56.02
42.86
4.00
2.00
Mutant Reverse Primer 5':
AGAAGTCCATCACATCTCCAC
321
21
56.55
47.62
4.00
0.00
Common Forward Primer 5':
AACAAAGAATTTGATTCGGA
90
20
54.86
30.00
5.00
3.00
Product Size: 232
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 3
: =ER/EK2
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
GAAGTCCATCACATCTCCAT
320
20
54.73
45.00
3.00
2.00
Mutant Reverse Primer 5':
GAAGTCCATCACATCTCCAC
320
20
55.27
50.00
3.00
0.00
Common Forward Primer 5':
CAAAGAATTTGATTCGGAGT
92
20
54.44
35.00
5.00
3.00
Product Size: 229
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------------Oligo 4
:
Pos.
Len.
Tm
GC%
Self Any
Self End
Wildtype Reverse Primer 5':
AGTCCATCACATCTCCAT
318
18
50.22
44.44
2.00
2.00
Mutant Reverse Primer 5':
AGTCCATCACATCTCCAC
318
18
50.73
50.00
2.00
0.00
Common Forward Primer 5':
AAGAATTTGATTCGGAGTTA
94
20
51.70
30.00
5.00
3.00
Product Size: 225
In-silico PCR Accepted: There is only one PCR product in the current human
genome.
------------------------------------------------------------------------------

iv. BclI
AS Primer Picking Result for SNP2015-01-23
Input sequence 5':
ACCTCTGGAGGACAGATGTACCACTATGACATGAATACAGCATCCCTTTCTCAACA
GCAGGATCAGAAGCCTATTTTTAATGTCATTCCACCAATTCCCG

TTGGTTCCGAAAATTGGAATAGGTGCCAAGGATCTGGAGATGACAACTTGACTTCT
CTGGGGACTCTGAACTTCCCTGGTCGAACAGTTTTTTCTAATGG
CTATTCAAGGTAAGATCAGTGTTTTTCTGTTTCTTAAGAATGGTACATTTAAGGTAGA
TTAATAGATGTAAATCTTCATTGATTTATATGTGTTCTCTAA
AGATTCATGTGCTTTTTTATATGAATAAGTTTAAGTGGCCTTTTGAAAGTAGGAAAGG
TAGACAACCTAAGTGACATCTGTACGTAACCATTTCAGGTTT
TTTCCTTAAATAGTGGTTTTCAGTATCCCATTGGCCAACGGTGAGGATTTTATTTAAC
ATTTTTAAAATAATGTTGCTCATTAACAGATATCTTAACGAA
AAATTATATAAATTCAGGAGAGTATAATGTCTCATAATATCATATTGTGTTGTGCATG
GTCATTCAGCTGTTTTAGAATATGTTCTTATATTACAATAAA
TGATACCCTTACTTACATAGTCAAAAGTTGTGCTGCCTTATTTGTAAATTCGTTAAGT
GTTAGCTTGAGATTAAAGAGTTAAAAGCAGAAGTACTAACAA
AGAGCCCTATTCTTCAAACTGAATCTTCTGTTAAAGAATTTGAGTTTTGAAGTTGCTA
AAGCAATGCAGTGAACAGTGTACCAGACCATAGTATTAGACA
CAGGTCTTGCTCACAGGGTTCTTGCCATAAAGTAGACAAGTTATGTCTGCTGAT[C/G
]AATCTCTTTAAGAGAGGAATTGGTGTCAACATGGTGCAAAA
CAAAATTTTACGTTCAAATGTTCCTGCAAGTTCTCAAGTAGATAACTGATGGCCAAA
ATTGTTAAGCTTCAATTTTCAGCTTTCGTTTGATTTTTCTCTT
TTTTTTACTCAGTCGTTTATAAGCATACTGATATTTTTGTCTGACCCAAAAAGGTCAG
AAAATGGAATTATCAGAAAAAAGTTCTAAATGTAGATATACG
TGTTGGTAGGGGTGAATTTCTCTACCCCGTAACCTCATCCCCAATTCAGATAAATGC
TAGGTTTTATATCCATTTTAGTTGTGAAGGAAAATATAAAAAT
GTGGATTGTAGTGACACAAGATTGATTAATCAGCGGGTTTTTTTAAAAGAAGACATG
GTAGACAGTGATTTATTTGTATGTAACTATTGAAGTTTTTTCT
TAAATGTTAGTGATATTCATCGTTCCCATTAACTAGTTATTCAGATTTTTGAAAATCCT
TTTTCTGTGAAAGCTATCCTAACCTGGAGGATGTCTCTTTT
CTTTCCTCTGTACTTAAGAAGCTTTTCTTGTTAGGGAAATAATTTAGAATTAGATTTA
GGCTATGTTCTGTTCTTCTAAAAGGCTTAGTTGTCAAAAAAA
AAAAAAAAAAAACCAAAAAACCTTGGTTCTTACATGTCTTAATGTGAACTACCTCCTA
ATCTATTGTTTAAATAATTATCCTTTATTTAGAAGAACACTA
CTTCAACCTGAGTTGAAGGTTTAAAATCTTTTCAGTAAGGAGATTTGAGATCTTTATT
ATTGCATAAGCTGTTGTGTTTTAAATGCTAAAAGACATGCTG
TGTTTTAAAATTTTCAATTGCAAATTTTTGGCAATAGAATTCGCATACTTGGTTTTCTT
AAAAGAGTTAAGTACGGTTGATTTGACTAAGCTATCTGTAG
GAAACTCTTAAATTGATTTATAAAACATGTAATTATACAAAGAAAAATAAAACATCTTA
GGAAACTCTTGGGGATTATTAATGGATTTTGCCCTGATAAT
CATCATGGCATGGTTTTCATTTTCCTTACTATAAAGAAAAGGCAAGGGACAAAACTT
ATT
Sequence Size: 1956
Primer Picking Parameters:
Primer Size
Opt: 20 Min: 18 Max: 36
GC%
Opt: 50.0 Min: 20.0 Max: 85.0
Tm
Opt: 55.0 Min: 40.0 Max: 65.0
Max Tm Diff:
100.0
Max Self Complementarity: 8.0
Max 3' Complementarity: 5.0
Max PolyX in Primer:
3
Number Primer Return: 5

Mismatch at the penultimate primer position: 'Yes'
In-silico PCR Filtering: 'No'
Mispriming Filtering: 'No'
Oligo 1 :
Any Self End
Wildtype Forward Primer 5':
AGTAGACAAGTTATGTCTGCTGACC
0
Mutant Forward Primer 5':
AGTAGACAAGTTATGTCTGCTGACG
00
Common Reverse Primer 5':
AAATCAAACGAAAGCTGAAA
Product Size: 159

Pos.

Len.

831

25

831
989

Tm
58.13

25

20

GC% Self
44.00

59.10

55.26

8.00

44.00

30.00

4.0

8.00

4.00

4.

0.00

-------------------------------------------------------------------------------------Oligo 2 :
End
Wildtype Forward Primer 5':
GTAGACAAGTTATGTCTGCTGACC
Mutant Forward Primer 5':
GTAGACAAGTTATGTCTGCTGACG
Common Reverse Primer 5':
AAATCAAACGAAAGCTGAAA
Product Size: 158

Pos.

Len.

832

24

832
989

Tm
57.14

24

20

GC% Self Any Self
45.83

58.16

55.26

6.00

45.83

30.00

4.00

6.00

4.00

4.00

0.00

-------------------------------------------------------------------------------------Oligo 3 :
End
Wildtype Forward Primer 5':
TAGACAAGTTATGTCTGCTGACC
Mutant Forward Primer 5':
TAGACAAGTTATGTCTGCTGACG
Common Reverse Primer 5':
AAATCAAACGAAAGCTGAAA
Product Size: 157

Pos.

Len.

Tm

833

23

56.23

833
989

23
20

GC% Self Any Self
43.48

57.29
55.26

43.48
30.00

6.00
6.00
4.00

4.00
4.00
0.00

-------------------------------------------------------------------------------------Oligo 4 :
End
Wildtype Forward Primer 5':
AGACAAGTTATGTCTGCTGACC
Mutant Forward Primer 5':
AGACAAGTTATGTCTGCTGACG

Pos.

Len.

834

22

834

22

Tm
56.07
57.17

GC% Self Any Self
45.46
45.46

6.00
6.00

4.00
4.00

Common Reverse Primer 5':
TTGACACCAATTCCTCTCTT
Product Size: 51

884

20

54.73

40.00

4.00

0.00

-------------------------------------------------------------------------------------Oligo 5 :
End
Wildtype Forward Primer 5':
GACAAGTTATGTCTGCTGACC
Mutant Forward Primer 5':
GACAAGTTATGTCTGCTGACG
Common Reverse Primer 5':
ACTTGAGAACTTGCAGGAAC
Product Size: 101

Pos.
835
835
935

Len.
21
21
20

Tm
54.85

GC% Self Any Self
47.62

56.01
54.53

47.62
45.00

6.00
6.00
4.00

4.00
4.00
2.00

--------------------------------------------------------------------------------------

v. RS 12086634
AS Primer Picking Result for rs12086634
Input sequence 5':
TGAGCAATCTCTCATTTAAGCCCCCCGTTACTTCAGAGACTACCCCCCAAAAATCTG
CAGCTAAGACTGATGCCATTTCTGCTGTATCACTGCAGGTGGT
ATCCCACTGCCTGGAGCTTGGAGCAGCCTCAGCACACTACATTGCTGGCACCATG
GAAGACATGACCTTCGCAGAGCAATTTGTTGCCCAAGCAGGAAAG
CTCATGGGTGAGGCTGTTTCTCTTACCTCCTCCTCTGAACTTTGCCCTTGGGGTCA
CCAAGAGCTTTTGGGAGGAGAATGGGAAAGGTATCAACCCCAGA
[G/T]GATTTCTTAATATAGCCATCTCTTGCAGGAGGACTAGACATGCTCATTCTCAAC
CACATCACCAACACTTCTTTGAATCTTTTTCATGATGATAT
TCACCATGTGCGCAAAAGCATGGAAGTCAACTTCCTCAGTTACGTGGTCCTGACTG
TAGCTGCCTTGCCCATGCTGAAGCAGAGCAATGGAAGCATTGTT
GTCGTCTCCTCTCTGGCTGGTAAGTGGGACAGGGACATATGTGGAAGGTAGAAGA
AAAAAAAAAATGCCAGGGATGATGCCAGGCTCTGAAGTAGACATA
AATTT
Sequence Size: 601
Primer Picking Parameters:
Primer Size
Opt: 20 Min: 18 Max: 36
GC%
Opt: 50.0 Min: 20.0 Max: 85.0
Tm
Opt: 57.0 Min: 40.0 Max: 65.0
Max Tm Diff:
100.0
Max Self Complementarity: 8.0
Max 3' Complementarity: 5.0
Max PolyX in Primer:
3
Number Primer Return: 5

Mismatch at the penultimate primer position: 'Yes'
In-silico PCR Filtering: 'No'
Mispriming Filtering: 'No'
Oligo 1 :
Any Self End
Wildtype Reverse Primer 5':
AAGAGATGGCTATATTAAGAAATTC
Mutant Reverse Primer 5':
AAGAGATGGCTATATTAAGAAATTA
0
Common Forward Primer 5':
TCTGCTGTATCACTGCAGGT
Product Size: 248

Pos.

Len.

325

Tm

25

53.90

325

25

20

56.96

78

GC% Self
28.00

52.46

5.00

24.00

50.00

5.00

4.00

8.00

2.0

4.00

-------------------------------------------------------------------------------------Oligo 2 :
End
Wildtype Reverse Primer 5':
AGAGATGGCTATATTAAGAAATTC
Mutant Reverse Primer 5':
AGAGATGGCTATATTAAGAAATTA
Common Forward Primer 5':
TCTGCAGCTAAGACTGATGC
Product Size: 271

Pos.

Len.

Tm

GC% Self Any Self

324

24

52.48

29.17

324
54

24

20

50.98

56.88

5.00

25.00

50.00

5.00

4.00

6.00

2.00

3.00

-------------------------------------------------------------------------------------Oligo 3 :
End
Wildtype Reverse Primer 5':
GAGATGGCTATATTAAGAAATTC
Mutant Reverse Primer 5':
GAGATGGCTATATTAAGAAATTA
Common Forward Primer 5':
TGATGCCATTTCTGCTGTAT
Product Size: 256

Pos.

Len.

Tm

323

23

51.32

323
68

23

20

GC% Self Any Self
30.44

49.76

56.74

5.00

26.09

40.00

5.00

4.00

5.00

2.00

2.00

-------------------------------------------------------------------------------------Oligo 4 :
End
Wildtype Reverse Primer 5':
AGATGGCTATATTAAGAAATTC
Mutant Reverse Primer 5':
AGATGGCTATATTAAGAAATTA

Pos.
322
322

Len.
22
22

Tm
49.40
47.81

GC% Self Any Self
27.27
22.73

5.00
4.00

5.00
2.00

Common Forward Primer 5':
TCTGCAGCTAAGACTGATGC
Product Size: 269

54

20

56.88

50.00

6.00

3.00

-------------------------------------------------------------------------------------Oligo 5 :
End
Wildtype Reverse Primer 5':
GATGGCTATATTAAGAAATTC
Mutant Reverse Primer 5':
GATGGCTATATTAAGAAATTA
Common Forward Primer 5':
TGATGCCATTTCTGCTGTAT
Product Size: 254

Pos.
321
321
68

Len.
21

48.01

21
20

Tm

GC% Self Any Self
28.57

46.36
56.74

23.81
40.00

5.00
4.00
5.00

5.00
2.00
2.00

--------------------------------------------------------------------------------------

F- Gel Electrophoresis Protocol

Pouring an agarose gel
Assembling the gel box
•
•

•

Turn the gel box so the electrodes are
facing you
Place the gel tray into the box
perpendicular to the box so that the
rubber gaskets on the side seal along the
Figure 3
edge of the box (figure 1)
There are 2 notches for the combs- make sure one set of notches is on the far
side of the gel box and one set is closer to you in the middle (see figure 2)

Making the gel
•

•
•

Measure 100ml 1XPE buffer with a
graduated cylinder and place in a 500ml
Erlinmeyer flask
Add 1g of agarose
Swirl, then microwave (for the microwave in
WLDC201 microwave for 1 minute and 15
seconds).

Figure 4

•

Remove from microwave with a hot glove, hold up to the light and swirl to
make sure everything is dissolved.

Pouring the gel
•

When the gel has cooled slightly, add 10ul of ethidium bromide solution to
100ml of gel, swirl, and then pour into the gel tray.
FROM THIS POINT FORWARD YOU MUST WEAR GLOVES WHEN TOUCHING THE
GEL OR THE BUFFER
• Place combs into the tray- the 12 well comb
should be at the top of the gel and the 20
well comb in the middle. Both should be
pointing to 1.5mm
• Allow the gel to solidify
• Immediately wash the flask out with hot
water. Failure to do so will result in residual Figure 5
agarose gelling in the bottom of the flask in
which case you will be severely mocked at lab meeting.

Running the gel
•
•
•
•
•
•

•

•

When the gel has solidified, turn the gel perpendicularly so that the 12 well
comb is on the left.
Add sufficient 1XPE to the gel box so that the
gel is completely submerged
Add 40ul ethidium bromide to the gel box on
the right hand side.
Load samples onto the gel and slide the lid
on.
Connect the electrodes to the power supply
Press the set button and check the current
Figure 6
(pun intended) settings. Make sure the dials
for Watts and Milliamps are at the max and set the voltage with the dial.
Press the start button and the light labeled DC should come on. A few
seconds later you should hear a pop and a few seconds after that you should
see bubbles in the gel box.
If the DC light fails to stay on, you may have a bad connection somewhere so
you should go back and recheck them all. Sometimes you might need to slide
the lid off and then back on again.

Disposing of the gel

PUT ON GLOVES
Remove the gel from the tray and place it on a blue absorbent pad in the hood.
When the gel has dried, place it in the yellow waste can in the common room near
the ice machine (WLDC207
Buffer should be poured down the drain and the gel tray and box should be rinsed
with DI water and placed back in the drawer

G- Collected Patient Data

i. Ellis

ii. Union Students

